Ozone at low concentrations does not affect motility and proliferation of cancer cells in vitro.
Journal
European journal of histochemistry : EJH
ISSN: 2038-8306
Titre abrégé: Eur J Histochem
Pays: Italy
ID NLM: 9207930
Informations de publication
Date de publication:
02 Apr 2020
02 Apr 2020
Historique:
received:
23
02
2020
accepted:
19
03
2020
entrez:
4
4
2020
pubmed:
4
4
2020
medline:
11
11
2020
Statut:
epublish
Résumé
Exposure to low ozone concentrations is used in medicine as an adjuvant/complementary treatment for a variety of diseases. The therapeutic potential of low ozone concentrations relies on their capability to increase the nuclear translocation of the Nuclear factor erythroid 2-related factor 2 (Nrf2), thus inducing the transcription of Antioxidant Response Elements (ARE)-driven genes and, through a cascade of events, a general cytoprotective response. However, based on the controversial role of Nrf2 in cancer initiation, progression and resistance to therapies, possible negative effects of ozone therapy may be hypothesised in oncological patients. With the aim to elucidate the possible changes in morphology, migration capability and proliferation of cancer cells following mild ozone exposure, we performed wound healing experiments in vitro on HeLa cells treated with low ozone concentrations currently used in the clinical practice. By combining a multimodal microscopy approach (light and fluorescence microscopy, scanning electron microscopy, atomic force microscopy) with morphometric analyses, we demonstrated that, under our experimental conditions, exposure to low ozone concentrations does not alter cytomorphology, motility and proliferation features, thus supporting the notion that ozone therapy should not positively affect tumour cell growth and metastasis.
Identifiants
pubmed: 32241095
doi: 10.4081/ejh.2020.3119
pmc: PMC7137928
doi:
Substances chimiques
Ozone
66H7ZZK23N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Med Gas Res. 2011 Dec 20;1:29
pubmed: 22185664
Acta Neurochir Suppl. 2011;108:123-5
pubmed: 21107948
Antioxid Redox Signal. 2019 May 10;30(14):1709-1730
pubmed: 30198307
Oncotarget. 2017 Jul 11;8(28):45484-45495
pubmed: 28525375
Toxicol In Vitro. 2017 Oct;44:100-110
pubmed: 28652203
Evid Based Complement Alternat Med. 2015;2015:480369
pubmed: 26357522
J Cell Physiol. 2018 Apr;233(4):2705-2714
pubmed: 28594115
J Med Life. 2012 Feb 22;5(1):59-67
pubmed: 22574088
Vopr Onkol. 2015;61(4):571-4
pubmed: 26571824
Eur J Pharmacol. 2014 Nov 5;742:158-62
pubmed: 25218903
Br J Pharmacol. 2014 Dec;171(24):5507-23
pubmed: 24665826
Science. 1996 Mar 29;271(5257):1821-2
pubmed: 8596947
Acta Cir Bras. 2016 Apr;31(4):256-63
pubmed: 27168538
Clin Cancer Res. 2015 Oct 15;21(20):4719-32
pubmed: 26078391
Haematologica. 2007 Sep;92(9):1289-90
pubmed: 17768133
Toxicol Appl Pharmacol. 2013 Feb 15;267(1):30-40
pubmed: 23253326
J Periodontal Implant Sci. 2018 Jun 30;48(3):136-151
pubmed: 29984044
Immunity. 2012 Dec 14;37(6):1037-49
pubmed: 23159440
Biomed Pharmacother. 2017 Apr;88:1090-1097
pubmed: 28192883
Int J Mol Sci. 2019 Aug 17;20(16):
pubmed: 31426459
Arch Med Res. 2005 Sep-Oct;36(5):549-54
pubmed: 16099337
Free Radic Biol Med. 2018 Aug 20;124:114-121
pubmed: 29864481
Nature. 2011 Jul 06;475(7354):106-9
pubmed: 21734707
Biochem Cell Biol. 2016 Dec;94(6):577-583
pubmed: 27842206
J Clin Gastroenterol. 1993 Sep;17(2):142-5
pubmed: 8409316
Free Radic Res. 2016 Sep;50(9):1022-31
pubmed: 27487012
Cell. 2016 Aug 11;166(4):963-976
pubmed: 27477511
Scand J Clin Lab Invest. 2011 May;71(3):185-92
pubmed: 21198421
Science. 2003 Dec 5;302(5651):1704-9
pubmed: 14657486
Toxicol Res. 2017 Jan;33(1):1-5
pubmed: 28133507
Eur J Histochem. 2015 Apr 21;59(2):2515
pubmed: 26150162
PLoS One. 2012;7(8):e41342
pubmed: 22876286
Mol Cell Biol. 2005 Jan;25(1):162-71
pubmed: 15601839
Anticancer Res. 2017 Feb;37(2):425-435
pubmed: 28179287
J Transl Med. 2011 May 17;9:66
pubmed: 21575276
Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):8030-8033
pubmed: 30536352
Eur J Pharmacol. 2018 Sep 15;835:82-93
pubmed: 30075224
Evid Based Complement Alternat Med. 2018 Sep 9;2018:7931849
pubmed: 30271455
Oncotarget. 2016 Nov 29;7(48):78804-78812
pubmed: 27788496
Free Radic Biol Med. 2015 Dec;89:147-57
pubmed: 26393425
Cancer Cell. 2012 Jul 10;22(1):66-79
pubmed: 22789539
Nat Cell Biol. 2013 Nov;15(11):1307-16
pubmed: 24142103
Oncogene. 2010 Jun 24;29(25):3703-14
pubmed: 20440267
FEBS J. 2018 Jan;285(1):8-27
pubmed: 28548369
Interv Neuroradiol. 2016 Dec;22(6):736-740
pubmed: 27485047
Eur J Pharmacol. 2017 Sep 15;811:148-154
pubmed: 28623000
Am J Dent. 2016 Oct;29(5):251-254
pubmed: 29178736
Dev Cell. 2014 Feb 10;28(3):239-52
pubmed: 24486154
PLoS One. 2017 Jul 24;12(7):e0179185
pubmed: 28738079
Cell Adh Migr. 2014;8(5):440-51
pubmed: 25482647